These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1862165)

  • 21. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients.
    Joober R; Rouleau GA; Lal S; Bloom D; Lalonde P; Labelle A; Benkelfat C
    Schizophr Res; 2005 Sep; 77(1):35-41. PubMed ID: 16005383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preschizophrenics: adding to the evidence, sharpening the focus.
    Ambelas A
    Br J Psychiatry; 1992 Mar; 160():401-4. PubMed ID: 1562869
    [No Abstract]   [Full Text] [Related]  

  • 23. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia.
    Tandon R; Goldman RS; Goodson J; Greden JF
    Biol Psychiatry; 1990 Jun; 27(12):1323-6. PubMed ID: 2364120
    [No Abstract]   [Full Text] [Related]  

  • 24. Personality disorders among the relatives of schizophrenia patients.
    Maier W; Lichtermann D; Minges J; Heun R
    Schizophr Bull; 1994; 20(3):481-93. PubMed ID: 7973465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Occupations, factors, and schizophrenia.
    Muntaner C
    Schizophr Bull; 1996; 22(1):11-3. PubMed ID: 8685654
    [No Abstract]   [Full Text] [Related]  

  • 26. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
    Hollister LE; Kim DY
    Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Childhood antecedents of stable positive symptoms in schizophrenia.
    Roff JD; Knight RA
    Psychol Rep; 1995 Aug; 77(1):323-9. PubMed ID: 7501772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk-benefit ratio of the proposed DSM-5 attenuated psychosis syndrome.
    Woods SW; McGlashan TH
    Am J Psychiatry; 2011 Dec; 168(12):1338; author reply 1338. PubMed ID: 22193675
    [No Abstract]   [Full Text] [Related]  

  • 29. The course of DSM-III-R schizophreniform disorder.
    Sautter F; McDermott B; Garver D
    J Clin Psychol; 1993 May; 49(3):339-44. PubMed ID: 8315035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychiatric disorders in the families of schizotypal subjects.
    Battaglia M; Gasperini M; Sciuto G; Scherillo P; Diaferia G; Bellodi L
    Schizophr Bull; 1991; 17(4):659-68. PubMed ID: 1805355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early treatment events and prediction of response to neuroleptics in schizophrenia.
    Awad AG; Hogan TP
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):585-8. PubMed ID: 2868492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obsessive-compulsive disorder and schizophrenia in three identical twin pairs.
    Lewis SW; Chitkara B; Reveley AM
    Psychol Med; 1991 Feb; 21(1):135-41. PubMed ID: 2047489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early response to haloperidol treatment in chronic schizophrenia.
    Stern RG; Kahn RS; Harvey PD; Amin F; Apter SH; Hirschowitz J
    Schizophr Res; 1993 Aug; 10(2):165-71. PubMed ID: 8398949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited.
    Volavka J; Douyon R; Convit A; Czobor P; Cooper TB
    Arch Gen Psychiatry; 1992 Dec; 49(12):999-1000. PubMed ID: 1449388
    [No Abstract]   [Full Text] [Related]  

  • 36. Toward a better identification and treatment of schizophrenia prodrome.
    Bota RG; Sagduyu K; Filin EE; Bota DA; Munro S
    Bull Menninger Clin; 2008; 72(3):210-27. PubMed ID: 18990056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum haloperidol concentration and clinical response in schizophrenia.
    Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
    Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ
    J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.